Endonovo Therapeutics, Inc.
Cash Flow Statement
| Line Item | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-18.5M | $-3.1M | $-395.6K | $-17.3M | $-6.4M | $-10.8M | $-5.3M | $-6.8M |
| Depreciation & Amortization | $646.9K | $648.5K | $651.2K | $650.3K | $650.2K | $14.8K | $15.8K | $14.8K |
| Depreciation | — | $1.6K | $4.3K | $3.4K | $3.3K | $14.8K | $15.8K | $14.8K |
| Amortization | $646.9K | $646.9K | $646.9K | $646.9K | — | — | — | — |
| Stock-Based Compensation | — | $0 | $57.4K | $31.0K | — | — | — | — |
| Net Cash from Operating Activities | $-678.8K | $-986.6K | $-741.6K | $-2.5M | $-2.9M | $-3.0M | $-2.5M | $-1.0M |
| Investing Activities | ||||||||
| Capital Expenditures | — | — | — | $2.6K | $9.0K | — | — | $3.8K |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | — | — | — | $-2.6K | $-9.0K | $-3.0M | — | $-3.8K |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $593.0K | $1.1M | $736.1K | $2.2M | $3.2M | $6.0M | $2.5M | $1.1M |
| Net Change in Cash | $-85.8K | $72.5K | $-5.5K | $-360.3K | $289.0K | $34.6K | $14.1K | $40.5K |
| Free Cash Flow | — | — | — | $-2.5M | $-2.9M | — | — | $-1.0M |